We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+7.22%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$459M
AUM Growth
+$102M
Cap. Flow
+$108M
Cap. Flow %
23.61%
Top 10 Hldgs %
84.41%
Holding
25
New
8
Increased
7
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$57.4M
2
CBAY
Cymabay Therapeutics
CBAY
+$12M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$10.7M
4
SLDB icon
Solid Biosciences
SLDB
+$7.61M
5
AIMT
Aimmune Therapeutics
AIMT
+$5.99M

Top Sells

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$3.67M
2
ASND icon
Ascendis Pharma A/S
ASND
+$1.93M
3
PACB icon
Pacific Biosciences
PACB
+$1.18M

Sector Composition

Rank Sector Weight
1 Healthcare 53.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$106M 23.06%
1,950,477
– –
RCUS icon
2
Arcus Biosciences
RCUS
$3.38B
$42.1M 9.17%
+3,445,461
New +$57.4M
IMMU
3
DELISTED
Immunomedics Inc
IMMU
$39.4M 8.6%
2,700,000
– –
ALDR
4
DELISTED
Alder Biopharmaceuticals
ALDR
$37.4M 8.14%
2,942,130
+95,000
+3% +$1.37M
AKAO
5
DELISTED
Achaogen Inc
AKAO
$36.9M 8.04%
2,850,000
+475,000
+20% +$5.39M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$36.7M 7.99%
400,000
– –
AIMT
7
DELISTED
Aimmune Therapeutics
AIMT
$29.8M 6.49%
935,020
+170,196
+22% +$5.99M
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
$20.3M 4.42%
1,562,040
+962,040
+160% +$12M
ASND icon
9
Ascendis Pharma A/S
ASND
$16.4B
$19.8M 4.3%
302,009
-34,255
-10% -$1.93M
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$19.2M 4.18%
392,789
+87,602
+29% +$4.55M
EPZM
11
DELISTED
Epizyme, Inc
EPZM
$17.7M 3.86%
998,278
– –
VRNA
12
DELISTED
Verona Pharma
VRNA
$11.3M 2.46%
565,292
+36,870
+7% +$533K
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$10.9M 2.38%
278,753
– –
BOLD
14
DELISTED
Audentes Therapeutics, Inc
BOLD
$9.48M 2.07%
+315,331
New +$10.7M
ACRS icon
15
Aclaris Therapeutics
ACRS
$739M
$5.47M 1.19%
312,368
+99,418
+47% +$2.11M
WVE icon
16
Wave Life Sciences
WVE
$1.14B
$3.01M 0.66%
75,000
-87,347
-54% -$3.67M
SGMO
17
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.94M 0.64%
+154,462
New +$3.3M
BHVN
18
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.72M 0.59%
105,706
– –
AKAO
19
PUT
DELISTED
Achaogen Inc
AKAO
$2.6M 0.57%
+200,000
New +$2.27M
SLDB icon
20
Solid Biosciences
SLDB
$775M
$2.02M 0.44%
+22,526
New +$7.61M
FBRX icon
21
Forte Biosciences
FBRX
$1.57B
$1.76M 0.38%
396
– –
ARDX icon
22
Ardelyx
ARDX
$1.25B
$1.03M 0.22%
+203,592
New +$1.27M
BDSI
23
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$338K 0.07%
+150,004
New +$351K
RARX
24
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$266K 0.06%
+50,000
New +$357K
PACB icon
25
Pacific Biosciences
PACB
$435M
– –
-447,520
Closed -$1.18M

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q1 2018 Portfolio in Review

As of Q1 2018, Foresite Capital Management III held 25 positions worth $459M, up 29% from $356M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Foresite Capital Management III deployed $108M of net new capital in Q1 2018, opening 8 new positions and adding to 7 existing holdings. Its largest new stake was Arcus Biosciences: 3,445,461 shares worth $42.1M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, up from 40% a quarter earlier.

On the sell side, the largest reduction was Wave Life Sciences, an estimated $3.67M trimmed.

  • Foresite Capital Management III's largest Q1 2018 buy was Arcus Biosciences: 3,445,461 shares worth $42.1M.
  • Foresite Capital Management III added most to Cymabay Therapeutics in Q1 2018, an estimated $12M increase.
  • Foresite Capital Management III's biggest Q1 2018 reduction was Wave Life Sciences, cutting an estimated $3.67M.
  • Foresite Capital Management III fully exited Pacific Biosciences in Q1 2018, selling an estimated $1.18M.
  • Foresite Capital Management III's ten largest holdings make up 84% of its $459M portfolio in Q1 2018.
  • Foresite Capital Management III opened 8 new positions and closed 1 in Q1 2018.
  • Foresite Capital Management III's portfolio value rose 29% quarter-over-quarter to $459M.

Based on Foresite Capital Management III's 13F filing for Q1 2018, filed 15 May 2018.